Author Correction: Attributes and predictors of long COVID

Sudre, Carole H.; Murray, Benjamin; Varsavsky, Thomas; Graham, Mark S.; Bowyer, Ruth C E; Pujol, Joan Capdevila; Kläser, Kerstin; Antonelli, Michela; Canas, Liane S; Molteni, Erika; Modat, Marc; Cardoso, M. Jorge; May, Anna; Ganesh, Sajaysurya; Davies, Richard; Nguyen, Long H.; Drew, David A.; Astley, Christina M; Joshi, Amit D.; Merino, Jordi; Tsereteli, Neli; Fall, Tove; Gomez, Maria F.; Duncan, Emma L.; Menni, Cristina; Williams, Frances; Franks, Paul W.; Chan, Andrew T.; Wolf, Jonathan; Ourselin, Sébastien; Spector, Tim D.; Steves, Claire J.

doi:10.1038/s41591-021-01361-2

Cited by 41 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, all available studies are retrospective, most of them are corrupted by either the lack of propensity score matching and “channeling bias” so that most of the existing results on each class of drugs are driven by the phenotype of patients likely to receive that specific drug by prescription. Another critical problem is the long-COVID [ 8 ], which can have unpredictable organ damage and outcomes, especially in patients with diabetes (Fig. 4 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Managing diabetes in diabetic patients with COVID: where do we start from?

2021

View full text Add to dashboard Cite

Aims COVID-19 has and still is sweeping away the national health systems worldwide. In this review, we sought to determine the evidence base proofs on the antidiabetic treatment capable to reduce the risk of COVID-19-related mortality. Methods We have performed a systematic search of published articles using PubMed, and EMBASE from March 2020 to March 31st, 2021. We excluded editorials, commentary, letters to the editor, reviews, and studies that did not have mortality as an outcome. For metformin and insulin only, we performed a meta-analysis using Cochrane RevMan 5.2. Results Among antidiabetic drugs, metformin was the only drug associated with a reduced risk of mortality. Conversely, insulin appears associated with an increased risk. The other classes of drugs were neutral. Conclusions The totality of articles reports retrospective data strongly affected by “channeling bias” so that most of the existing results on each class of drugs are driven by the phenotype of patients likely to receive that specific drug by prescription.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Notably, patients with more severe illnesses, such as those with diabetes, might experience long-term damage. The lasting effects of COVID-19 are now called “long COVID,” a distinct syndrome, probably determined by a dysfunctional immune-inflammatory response, affecting even people who were never hospitalized for COVID-19 [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Managing diabetes in diabetic patients with COVID: where do we start from?

2021

View full text Add to dashboard Cite

show abstract

“…The sleep disturbances were reported more in the female sex, which increases during the COVID-19 infection but decreases with time after the recovery [37][38][39]; for example, insomnia has been improved three months after recovery [38,40]. Sami et al [41] reported that sleep disturbances are independent of the severity of acute COVID-19; however, other works showed that the severity of acute COVID-19 is a predictor of those disturbances [42,43].…”

Section: Sleep and Stress Disordersmentioning

confidence: 98%

Neuropsychiatric Disorders and COVID-19: What We Know So Far

et al. 2021

View full text Add to dashboard Cite

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) affects the central nervous system (CNS), which is shown in a significant number of patients with neurological events. In this study, an updated literature review was carried out regarding neurological disorders in COVID-19. Neurological symptoms are more common in patients with severe infection according to their respiratory status and divided into three categories: (1) CNS manifestations; (2) cranial and peripheral nervous system manifestations; and (3) skeletal muscle injury manifestations. Patients with pre-existing cerebrovascular disease are at a higher risk of admission to the intensive care unit (ICU) and mortality. The neurological manifestations associated with COVID-19 are of great importance, but when life-threatening abnormal vital signs occur in severely ill COVID-19 patients, neurological problems are usually not considered. It is crucial to search for new treatments for brain damage, as well as for alternative therapies that recover the damaged brain and reduce the inflammatory response and its consequences for other organs. In addition, there is a need to diagnose these manifestations as early as possible to limit long-term consequences. Therefore, much research is needed to explain the involvement of SARS-CoV-2 causing these neurological symptoms because scientists know zero about it.

show abstract

“…With large numbers of the global population exposed to a potential viral trigger during this current SARS-CoV-2 pandemic, it is reasonable to suppose that a significant number of people with long-COVID may have, or will develop, ME/CFS. It is estimated that 1 in 10 people are experiencing persistent symptoms for over 12 weeks (87), often despite a relatively "mild" acute illness and reports of previously healthy lifestyles (88,89), and are consequently diagnosed with long-COVID, post-COVID fatigue, or long-COVID fatigue syndrome (LCFS) (72,73,90).…”

Section: Managementmentioning

confidence: 99%

A Natural History of Disease Framework for Improving the Prevention, Management, and Research on Post-viral Fatigue Syndrome and Other Forms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

et al. 2022

View full text Add to dashboard Cite

We propose a framework for the treatment, rehabilitation, and research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using a natural history of disease approach to outline the distinct disease stages, with an emphasis on cases following infection to provide insights into prevention. Moving away from the method of subtyping patients based on the various phenotypic presentations and instead reframing along the lines of disease progression could help with defining the distinct stages of disease, each of which would benefit from large prospective cohort studies to accurately describe the pathological mechanisms taking place therein. With a better understanding of these mechanisms, management and research can be tailored specifically for each disease stage. Pre-disease and early disease stages call for management strategies that may decrease the risk of long-term morbidity, by focusing on avoidance of further insults, adequate rest to enable recovery, and pacing of activities. Later disease stages require a more holistic and tailored management approach, with treatment—as this becomes available—targeting the alleviation of symptoms and multi-systemic dysfunction. More stringent and standardised use of case definitions in research is critical to improve generalisability of results and to create the strong evidence-based policies for management that are currently lacking in ME/CFS.

show abstract

Author Correction: Attributes and predictors of long COVID

Cited by 41 publications

References 0 publications

Managing diabetes in diabetic patients with COVID: where do we start from?

Managing diabetes in diabetic patients with COVID: where do we start from?

Neuropsychiatric Disorders and COVID-19: What We Know So Far

A Natural History of Disease Framework for Improving the Prevention, Management, and Research on Post-viral Fatigue Syndrome and Other Forms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Contact Info

Product

Resources

About